Philipps University of Marburg, Marburg, Germany. RATIONALE: The majority of asthma exacerbations, especially in childhood, as well as more than 50% of common cold cases are caused by infections with human rhinoviruses (RVs). So far, there are no FDAapproved therapeutics directed specifically against HRVs. Using DNAzyme technology, our aim was to develop a specific antirhinoviral candidate drug. METHODS: By use of three representative strains (RVA1, RVA16, and RVA29) candidate DNAzymes were designed against 5'-untranslated (5'-UTR) as well as cis-acting replication element (CRE), two highly conserved regions of genomic RV RNA. In total, 226 DNAzyme candidates were screened for their cleavage efficacy against viral RNA in a cell-free in vitro assay. Then, 322 published rhinoviral genomic sequences were analyzed for complementarity with most active DNAzymes. Most promising candidates with broad strain coverage were further molecularly optimized. Next, potential cytotoxic as well as unspecific immune stimulatory activities were examined in HEK293 cells. Antiviral efficacy of non-toxic DNAzyme candidate was analyzed in infected human bronchial BEAS-2B cells and ex vivo-cultured human sinonasal tissue. RESULTS: Screened candidate DNAzymes were characterized by either good catalytic activity or by high HRV strain coverage. Binding domains of two lead candidates were modified in length which resulted in significantly improved cleavage efficiency and highly favorable cytotoxic/immune stimulatory profile combined with superior strain coverage (about 98%). Treatment of BEAS-2B cells and sinonasal tissue with the candidate DNAzyme Dua-01-L12R9 led to significantly decreased HRV propagation. CONCLUSIONS: In future, asthma exacerbations might be prevented by use of the specific and efficient antirhinoviral DNAzyme Dua-01-L12R9.
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Reduced Genentech, Inc., South San Francisco, CA. RATIONALE: Uncontrolled allergic asthma is responsible for increased asthma-related health care resource utilization (HCRU). The effect of omalizumab treatment on asthma exacerbations and asthma-related HCRU was examined using data from the real-world Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab (PROSPERO) study. METHODS: PROSPERO was a US-based, 48-week, multicenter, prospective, observational study. Patients aged > _12 years with allergic asthma initiated omalizumab based on physician-assessed need. Asthma exacerbations (worsening of asthma symptoms requiring oral corticosteroids, emergency department [ED] visit or hospitalization), asthma-related hospital admissions, ED visits, and unscheduled physician's office visits at baseline and study end were compared. RESULTS: Of 806 enrolled patients, 801 were treated with omalizumab for a mean [SD] of 9.7 [3.4] months (median: 11.2 months). Patients were primarily female (63.5%), and white (70.3%). Asthma exacerbation data for 796 patients were available at baseline and end of study. After initiation of omalizumab, patients experienced a 74% reduction in asthma exacerbations during the study compared to the 12 months prior to study entry. The mean (SD) number of asthma-related hospital admissions, ED visits, and unscheduled physician's office visits decreased from 0.1 (0.45), 0.3 (0.77), and 0.6 (1.13) within 90 days prior to baseline to 0.06 (0.35), 0.14 (0.56) and 0.39 (0.86) after 12 months of omalizumab treatment, respectively. No new safety issues were identified. CONCLUSIONS: Patients in the real-world treated with omalizumab experienced meaningful improvements in asthma control (measured by mean number of asthma exacerbations) and reductions in asthma-related HCRU providing important data supporting omalizumab use.
